Nymox Pharmaceutical Stock Forecast, Price & News

-0.20 (-9.57 %)
(As of 09/17/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume269,200 shs
Average Volume303,956 shs
Market Capitalization$155.70 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive NYMX News and Ratings via Email

Sign-up to receive the latest news and ratings for Nymox Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter.

Nymox Pharmaceutical logo

About Nymox Pharmaceutical

Nymox Pharmaceutical Corp. operates as a biopharmaceutical company, which engages in the research and development on products for the aging population. Its products include NicAlert and TobacAlert, and the NX-1207 for the treatment of low-grade localized prostate cancer. It operates through the following geographical segments: Canada, United States, and Europe. The company was founded by Paul Averback on May 30, 1995 and is headquartered in Nassau, the Bahamas.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.21 out of 5 stars

Medical Sector

1150th out of 1,349 stocks

Diagnostic Substances Industry

19th out of 25 stocks

Analyst Opinion: 0.0Community Rank: 4.4Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Nymox Pharmaceutical (NASDAQ:NYMX) Frequently Asked Questions

What stocks does MarketBeat like better than Nymox Pharmaceutical?

Wall Street analysts have given Nymox Pharmaceutical a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Nymox Pharmaceutical wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Nymox Pharmaceutical's next earnings date?

Nymox Pharmaceutical is scheduled to release its next quarterly earnings announcement on Friday, November 12th 2021.
View our earnings forecast for Nymox Pharmaceutical

How were Nymox Pharmaceutical's earnings last quarter?

Nymox Pharmaceutical Co. (NASDAQ:NYMX) announced its quarterly earnings results on Friday, August, 13th. The biopharmaceutical company reported ($0.05) earnings per share (EPS) for the quarter.
View Nymox Pharmaceutical's earnings history

How has Nymox Pharmaceutical's stock been impacted by Coronavirus?

Nymox Pharmaceutical's stock was trading at $2.29 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, NYMX shares have decreased by 17.5% and is now trading at $1.89.
View which stocks have been most impacted by COVID-19

Who are Nymox Pharmaceutical's key executives?

Nymox Pharmaceutical's management team includes the following people:
  • Paul Averback, Chairman, President & Chief Executive Officer
  • Randall J. Lanham, COO, Secretary, Director & General Counsel
  • Erik Danielsen, Chief Financial Officer
  • Russell I. Thomson, Vice President-Quality & Regulatory Affairs

Who are some of Nymox Pharmaceutical's key competitors?

What other stocks do shareholders of Nymox Pharmaceutical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Nymox Pharmaceutical investors own include Quantum (QTM), Rocket Pharmaceuticals (RCKT), Biocept (BIOC), TherapeuticsMD (TXMD), Catalyst Pharmaceuticals (CPRX), MEI Pharma (MEIP), OPKO Health (OPK), Rigel Pharmaceuticals (RIGL), Synergy Pharmaceuticals (SGYP) and CTI BioPharma (CTIC).

What is Nymox Pharmaceutical's stock symbol?

Nymox Pharmaceutical trades on the NASDAQ under the ticker symbol "NYMX."

Who are Nymox Pharmaceutical's major shareholders?

Nymox Pharmaceutical's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Millennium Management LLC (0.39%), Ergoteles LLC (0.23%), Tibra Equities Europe Ltd (0.18%), Morgan Stanley (0.09%), Morgan Stanley (0.09%) and Goldman Sachs Group Inc. (0.06%).
View institutional ownership trends for Nymox Pharmaceutical

Which institutional investors are selling Nymox Pharmaceutical stock?

NYMX stock was sold by a variety of institutional investors in the last quarter, including State Street Corp, Geode Capital Management LLC, JPMorgan Chase & Co., Bank of America Corp DE, and Parametric Portfolio Associates LLC.
View insider buying and selling activity for Nymox Pharmaceutical
or view top insider-selling stocks.

Which institutional investors are buying Nymox Pharmaceutical stock?

NYMX stock was acquired by a variety of institutional investors in the last quarter, including Millennium Management LLC, Ergoteles LLC, Tibra Equities Europe Ltd, Boothbay Fund Management LLC, Goldman Sachs Group Inc., Morgan Stanley, Morgan Stanley, and Simplex Trading LLC.
View insider buying and selling activity for Nymox Pharmaceutical
or or view top insider-buying stocks.

How do I buy shares of Nymox Pharmaceutical?

Shares of NYMX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Nymox Pharmaceutical's stock price today?

One share of NYMX stock can currently be purchased for approximately $1.89.

How much money does Nymox Pharmaceutical make?

Nymox Pharmaceutical has a market capitalization of $155.70 million.

How many employees does Nymox Pharmaceutical have?

Nymox Pharmaceutical employs 3 workers across the globe.

What is Nymox Pharmaceutical's official website?

The official website for Nymox Pharmaceutical is

Where are Nymox Pharmaceutical's headquarters?

Nymox Pharmaceutical is headquartered at BAY & DEVEAUX STREETS, NASSAU C5, H4M 2V2.

How can I contact Nymox Pharmaceutical?

Nymox Pharmaceutical's mailing address is BAY & DEVEAUX STREETS, NASSAU C5, H4M 2V2. The biopharmaceutical company can be reached via phone at (800) 936-9669 or via email at [email protected].

This page was last updated on 9/20/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.